Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2023-07-13 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2023年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2023 年第一次临时股东大会会议资料" which translates to "2023 First Extraordinary General Meeting (EGM) Meeting Materials". It contains detailed agenda items, meeting rules, voting procedures, and proposals to be discussed and voted on during the meeting. The content includes procedural instructions for shareholders, descriptions of proposals such as changes to company capital, amendments to company bylaws, and other governance-related rules. There is no financial data or earnings information, nor is it a transcript or announcement of results. The document is clearly the meeting materials provided for a shareholders' meeting, which fits the definition of AGM Information (AGM-R), as it is the presentation and materials shared during a general meeting (in this case, an extraordinary general meeting). The document length is sufficient and it is not merely an announcement of a report. Therefore, the correct classification is AGM Information (AGM-R).
2023-07-13 Chinese
安旭生物投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '杭州安旭生物科技股份有限公司 投资者关系管理制度' which translates to 'Investor Relations Management System of Hangzhou Anxu Biotechnology Co., Ltd.' It is a detailed policy document outlining the company's investor relations management practices, including communication with investors, disclosure principles, investor meetings, website management, analyst meetings, one-on-one communications, and related personnel responsibilities. It does not contain financial statements, earnings data, audit results, or any report publication announcements. It is a governance-related document focused on internal rules and procedures for managing investor relations and corporate governance compliance. Therefore, the most appropriate classification is Governance Information (CGR).
2023-07-05 Chinese
安旭生物监事会议事规则
Governance Information Classification · 100% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules' and details the rules and procedures for the supervisory board meetings of Hangzhou Anxu Biotechnology Co., Ltd. It includes sections on the composition and powers of the supervisory board, meeting proposals and notifications, meeting convening, voting, resolutions, and record keeping. There is no financial data, no mention of financial results, no regulatory filings or announcements, and no indication of it being a report or announcement of a report. The document is a governance-related internal rules document outlining the supervisory board's operational procedures. Therefore, it fits best under Governance Information (CGR). The document length is 4029 characters, which is sufficient for a detailed governance document, not a brief announcement or certification.
2023-07-05 Chinese
安旭生物关于变更注册资本、修订《公司章程》并办理工商变更登记手续的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding changes to the company's registered capital and amendments to the company's articles of association (company charter). It details the approval of capital increase through profit distribution and capital reserve conversion, specific amendments to the articles of association, and the authorization for the board to handle related registration procedures. The document includes detailed legal and procedural text about corporate governance and shareholder meeting rules, but it is not a full annual or interim financial report, nor an earnings release or audit report. It is a formal corporate announcement about capital changes and governance document amendments, which fits the category of Share Issue/Capital Change (SHA). The document length (8664 characters) and content indicate it is the announcement itself, not a brief notice or a report publication announcement. Therefore, the classification is SHA with high confidence.
2023-07-05 Chinese
安旭生物募集资金管理制度
Regulatory Filings Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the management, storage, usage, supervision, and regulatory compliance related to the company's raised funds. It references laws and regulations governing fundraising and capital use, outlines procedures for managing raised funds, and includes oversight mechanisms. The document is a policy or procedural manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, earnings data, voting results, or management changes. It is not a report publication announcement or a certification. The content fits best under a regulatory or compliance filing category that covers internal rules and procedures related to capital management. Given the options, the closest match is 'Regulatory Filings (RNS)' as a fallback category for filings that do not neatly fit elsewhere, especially since this is a regulatory compliance document about fundraising capital management.
2023-07-05 Chinese
安旭生物第二届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's second board meeting, including approvals of amendments to company bylaws, capital changes, and proposals to convene a shareholders' meeting. It details voting results and references further disclosures on the stock exchange website. The document is not a full report but an official announcement of board decisions and meeting outcomes. It does not contain financial statements or detailed financial data. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2023-07-05 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.